Regen BioPharma Advances Towards Breast Cancer Immunotherapy

Written by on August 5, 2014 in Featured on App, R&D, Therapeutic Vaccines with 5 Comments

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine

Regen BioPharma Has Reported Progress in Development of dCellVax: A Therapeutic Cancer Vaccine

On the 1st of August 2014, Regen BioPharma reported on progress on its therapeutic cancer vaccine dCellVax, which stimulates the immune system of patients to selectively kill tumors.

Thomas Ichim, the Chief Scientific Office of Regen BioPharma, said in a statement that ‘we are please to announce that Regen BioPharma has successfully achieved silencing of the IDO gene in human dendritic cells, which is a major step forward in development of our Investigational New Drug (IND) application to the FDA. ‘

The original developer of the technology behind dCellVax is Dr.Wei-Ping Min, a Professor at the University of Western Ontario. The patent for this therapy was originally assigned to Regen BioPharma by Dr.Min, who used dendritic cells whose genes were silenced in order to induce regression of breast cancer tumors in animal models.

The vaccine is based on extracting blood from patients , growing dendritic cells from it and then genetically modifying them to become resistant to cancer’s immune suppressive activity. In many cancers, the production of indolamine 2,3 deoxygensae (IDO) enzyme is stimulated, which dampens the immune system. Dendritic cells normally stimulate the immune system, but when they express IDO in cancer, they suppress the immune system. If a vaccine can be developed that provides an effective dose of dendritic cells silenced for IDO, then normal anti-tumor responses can be stimulated once again.

The CEO of Regen BioPharma, David Koos, has said that ‘we are optimistic that this data will lead to advancement of dCellVax into clinical trials,’

We are optimistic that this data will lead to advancement of dCellVax into clinical trialsDavid Kroos, CEO of Regen BioPharma

The CEO of the company also notes that ‘the smooth translation of this university acquired intellectual property into a commercial setting further supports the Regen BioPharma model of rapidly advancing patents that are sitting unnoticed in the technology transfer offices of universities.’

Only time will tell if the vaccine’s technology, which has thus far only been tested on animals, is safe for humans in the battle against cancer.

Read more about it here: Regen BioPharma Provides Update on dCellVax Breast Cancer Immunotherapy

 

Tags: , , , , ,

About the Author

About the Author: As a 4th year student studying Biology with management at Imperial College London, I have a passion for health issues and the microscopic world of bacteria and viruses. I'll be around for a while writing about the cutting edge issues that are shaping the pharmaceutical industry and medical progress around the world. .

Subscribe

If you enjoyed this article, subscribe now to receive more just like it.

Subscribe via RSS Feed Connect on Google Plus Join Our LinkedIn Group Connect on YouTube

5 Reader Comments

Trackback URL Comments RSS Feed

  1. H2ojetskier says:

    Regen BioPharma has some New cutting edge technology coming out. Great job Regen! Keep a eye on them more to come.

    • Abercrombie Smith says:

      Regen BioPharma is participating in a revolutionary area of science right now, with ramification so large, I have to think many companies do not want the science to succeed. Of course for the greater good, the potential benefits are astounding. It is an exciting time, and they seem close to some major breakthrough treatments.

  2. Krish Narayan says:

    successfully achieved silencing of the IDO gene in human dendritic cells is huge…this could very well be the turning point of medical science in manipulating the immune system

  3. Dr. Jason Danielson says:

    This truly is cutting edge, and could change the game of treatment procedures! Is this company trading on NASDAQ? if so, I want shares!

  4. Elmer McClung says:

    soon this will be a nasdaq stock they are doing great

Leave a Reply

Your email address will not be published. Required fields are marked *

Top
Geolocation